Purmorphamine decreases FSK-directed cAMP production in a cilium-independent manner. by Lan Ho Wei (5688020)

Participant characteristics (non-weighted). by Ruth Barclay (8428956)

Iberiotoxin treatment causes a significant decrease in the ascorbate/dehydroscorbate ratio in mucosal tissue (and a similar trend was observed in the detrusor). by Yi Wang (32470)

Regions (α-helices, β-sheets, and loops) showing an average increase or decrease of RMSF in the MTs compared to the WT; RMSF of a particular structure is taken to be increased or decreased if there is an average change in RMSF of >0.03 nm in at least ≥50% of its residues. by Kumaraswamy Naidu Chitrala (612025)

“…<p>Regions (α-helices, β-sheets, and loops) showing an average increase or decrease of RMSF in the MTs compared to the WT; RMSF of a particular structure is taken to be increased or decreased if there is an average change in RMSF of >0.03 nm in at least ≥50% of its residues.…”

Grade system. by Zhuoyang Xia (21354186)

“…We excluded non-randomized trials, studies without full texts, unrelated interventions, and those not reporting relevant outcomes. …”

Literature search. by Zhuoyang Xia (21354186)

“…We excluded non-randomized trials, studies without full texts, unrelated interventions, and those not reporting relevant outcomes. …”

Study characteristics. by Zhuoyang Xia (21354186)

“…We excluded non-randomized trials, studies without full texts, unrelated interventions, and those not reporting relevant outcomes. …”

Flowchart of literature retrieval. by Zhuoyang Xia (21354186)

“…We excluded non-randomized trials, studies without full texts, unrelated interventions, and those not reporting relevant outcomes. …”

Data extraction. by Zhuoyang Xia (21354186)

“…We excluded non-randomized trials, studies without full texts, unrelated interventions, and those not reporting relevant outcomes. …”

Cochrane Collaboration’s risk of bias tool. by Zhuoyang Xia (21354186)

“…We excluded non-randomized trials, studies without full texts, unrelated interventions, and those not reporting relevant outcomes. …”

DMB treatment improved neurological deficit and decreased infarct volume 24 h after MCAO. by Huinan Zhang (849524)

CD8 depletion fails to cause rebound in non-rebounding off-ART RMs. by Brandon F. Keele (7450001)

The material parameters of the 50 MPa concrete for the simulations [26]. by Xiaochao Jin (3993236)

Effect of the Hill coefficient on estimates of <i>ε</i>_max (left column) and IC₅₀ (right column) for the logistic model with drug applied to the growth rate <... by Hope Murphy (8843516)

3D snapshots of the tumor system with single-agent BHQ880 treatment at (a) time step 40, (b) time step 50 and (c) time step 120. by Minna Qiao (836556)

Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

“…</p><p>Results: In base case analysis, cemiplimab compared with pembrolizumab was associated with a gain of 0.44 quality-adjusted life-years (QALYs) and an increased cost of $23,084, resulting in an incremental cost-effectiveness ratio (ICER) of $52,998/QALY; cemiplimab compared with atezolizumab was associated with a gain of 0.13 QALYs and a decreased cost of $104,642, resulting in its dominance of atezolizumab. …”

Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF by Qiao Liu (346535)

“…</p><p>Results: In base case analysis, cemiplimab compared with pembrolizumab was associated with a gain of 0.44 quality-adjusted life-years (QALYs) and an increased cost of $23,084, resulting in an incremental cost-effectiveness ratio (ICER) of $52,998/QALY; cemiplimab compared with atezolizumab was associated with a gain of 0.13 QALYs and a decreased cost of $104,642, resulting in its dominance of atezolizumab. …”

Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

“…</p><p>Results: In base case analysis, cemiplimab compared with pembrolizumab was associated with a gain of 0.44 quality-adjusted life-years (QALYs) and an increased cost of $23,084, resulting in an incremental cost-effectiveness ratio (ICER) of $52,998/QALY; cemiplimab compared with atezolizumab was associated with a gain of 0.13 QALYs and a decreased cost of $104,642, resulting in its dominance of atezolizumab. …”

Cell type-specific expression of <i>mif</i>, <i>cd74a</i>, and <i>cd74b</i>. by Safia A. Essien (20108379)

Increasing BMI is associated with decreases in multiple leukocyte subsets in the peripheral blood of ccRCC subjects, whereas only classical monocytes and regulatory T cells are dim... by Justin T. Gibson (8910317)